tamsulosin prolonged release / Generic mfg. - LARVOL DELTA

Bioequivalence, Food-Effect Assessment and Exploratory IVIVC of Two Extended-Release Tamsulosin 0.4 mg Formulations in Healthy Mexican Subjects. (PubMed, Pharmaceutics) - P=N/A | "Comparable dissolution and IVIVC findings further support their reliability in vivo performance and therapeutic interchangeability. ClinicalTrials.gov identifiers: NCT07698288 and NCT07698275."

Journal • Benign Prostatic Hyperplasia • Hypotension

Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended-Release Capsules in Healthy Chinese Volunteers: A Randomized, Open-Label, Crossover Study Under Fasting and Fed Conditions. (PubMed, Clin Pharmacol Drug Dev) - "The geometric mean ratios and 90% confidence intervals for key exposure metrics for both formulations under fasting and fed conditions were within the 0.8000-1.2500 bioequivalence range. Both formulations demonstrated bioequivalence under both conditions, and no severe adverse events were observed."

Clinical • Journal • PK/PD data • Benign Prostatic Hyperplasia

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Berlin-Chemie AG Menarini Group | Not yet recruiting ➔ Recruiting

Enrollment open

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions (clinicaltrials.gov) - P1 | N=46 | Not yet recruiting | Sponsor: Berlin-Chemie AG Menarini Group

New P1 trial

A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State (clinicaltrials.gov) - P1 | N=33 | Active, not recruiting | Sponsor: Berlin-Chemie AG Menarini Group

New P1 trial

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Berlin-Chemie AG Menarini Group

New P1 trial

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions (clinicaltrials.gov) - P1 | N=46 | Active, not recruiting | Sponsor: Berlin-Chemie AG Menarini Group | Recruiting ➔ Active, not recruiting

Enrollment closed

Antibiotic therapy effectiveness as an outcome predictor of complex treatment in chronic prostatitis/chronic pelvic pain syndrome. (PubMed, Cent European J Urol) - "All patients orally received: diclofenac sodium (100 mg/day, 2 weeks), modified release tamsulosin (0.4 mg/day, 1 month), and alcohol extract of Serenoa repens (320 mg/day, 6 months). For CP/CPPS, the history of antibiotic efficacy determines the prognosis of current treatment. The latent bacterial factor is assumed in 24.3-27% of cases of CP/CPPS."

Journal • CNS Disorders • Depression • Gynecology • Immunology • Inflammation • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry